ValuEngine cut shares of Accelerate Diagnostics (NASDAQ:AXDX) from a hold rating to a sell rating in a research report sent to investors on Thursday morning, ValuEngine reports.

A number of other research analysts also recently commented on AXDX. JPMorgan Chase & Co. downgraded Accelerate Diagnostics from a neutral rating to an underweight rating and set a $16.00 target price on the stock. in a research note on Friday, September 27th. Piper Jaffray Companies lowered their target price on Accelerate Diagnostics from $22.00 to $19.00 and set a positive rating on the stock in a research note on Friday, August 9th. Finally, BidaskClub downgraded Accelerate Diagnostics from a sell rating to a strong sell rating in a research note on Saturday, November 2nd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. Accelerate Diagnostics currently has a consensus rating of Hold and a consensus price target of $18.67.

NASDAQ AXDX traded up $0.14 on Thursday, reaching $16.21. The stock had a trading volume of 209,200 shares, compared to its average volume of 245,035. The business has a 50 day moving average price of $17.17 and a 200 day moving average price of $18.97. The company has a current ratio of 21.93, a quick ratio of 18.89 and a debt-to-equity ratio of 12.81. Accelerate Diagnostics has a 1 year low of $10.23 and a 1 year high of $24.00. The company has a market capitalization of $860.11 million, a price-to-earnings ratio of -10.01 and a beta of 2.72.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its earnings results on Thursday, November 7th. The medical research company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. Accelerate Diagnostics had a negative return on equity of 249.46% and a negative net margin of 1,116.69%. The firm had revenue of $2.27 million for the quarter, compared to the consensus estimate of $3.15 million. On average, analysts anticipate that Accelerate Diagnostics will post -1.58 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the business. Nuveen Asset Management LLC lifted its position in shares of Accelerate Diagnostics by 12.9% in the second quarter. Nuveen Asset Management LLC now owns 448,289 shares of the medical research company’s stock worth $10,257,000 after buying an additional 51,304 shares during the last quarter. Chicago Capital LLC lifted its position in shares of Accelerate Diagnostics by 61.3% in the third quarter. Chicago Capital LLC now owns 881,390 shares of the medical research company’s stock worth $16,367,000 after buying an additional 335,111 shares during the last quarter. M&T Bank Corp acquired a new stake in shares of Accelerate Diagnostics in the second quarter worth about $206,000. TCI Wealth Advisors Inc. acquired a new stake in shares of Accelerate Diagnostics in the third quarter worth about $1,032,000. Finally, Griffin Asset Management Inc. lifted its position in shares of Accelerate Diagnostics by 48.1% in the third quarter. Griffin Asset Management Inc. now owns 814,749 shares of the medical research company’s stock worth $15,130,000 after buying an additional 264,703 shares during the last quarter. 54.48% of the stock is owned by institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Featured Story: Real Estate Investment Trust (REIT) ETF

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.